Janssen’s Tremyfa scores success in Phase III ulcerative colitis trial

Janssen has released new safety and efficacy data from a Phase III trial investigating Tremyfa (guselkumab) in adults with moderately to severely active ulcerative colitis (UC).

Tremyfa is a fully human immunoglobulin G1 lambda monoclonal antibody (mAb) that binds to the human interleukin (IL)-23 receptor.